Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rudy Malayil

Interventional Pain Medicine Huntington, WV Medical Doctor

NPI 1114151347 CMS profile 141460

2900 1St Ave, Opc Suite 210, Huntington, WV 25702

Open in the dashboard

General payments

$103,575

1,101 records reported · program years 2019–2025

Research payments

$460

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,808 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Rudy Malayil of Huntington, WV is reported in the CMS Open Payments database as having received $103,575 across 1,101 general payments and $460 in research payments paid to them. Separately, studies naming them as principal investigator received $16,808 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,601 108
2024 General $6,178 159
2023 General $4,872 168
2022 General $34,880 187
2021 General $32,656 206
2020 General $8,204 108
2020 Research $460 1
2019 General $13,186 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rudy Malayil
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Rudy Malayil were reported at $3,601. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Rudy Malayil Interventional Pain Medicine median Middle half National median
2019 $13,186 $684 $216–$2,079 $163
2020 $8,204 $382 $122–$1,109 $114
2021 $32,656 $552 $167–$1,554 $132
2022 $34,880 $605 $187–$1,924 $149
2023 $4,872 $671 $195–$1,915 $160
2024 $6,178 $684 $206–$1,837 $164
2025 $3,601 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $78,275 564 payments
  2. Medtronic, Inc. $14,693 145 payments
  3. Boston Scientific Corporation $2,368 162 payments
  4. Nevro Corp. $1,435 39 payments
  5. Relievant Medsystems, Inc. $1,052 10 payments
  6. US WorldMeds, LLC $654 13 payments
  7. Flowonix Medical Incorporated $596 2 payments
  8. Curonix LLC $545 11 payments
  9. Globus Medical, Inc. $527 11 payments
  10. Vertos Medical, Inc. $483 7 payments
  11. Other $2,949 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $39,550 37 payments
  2. Food and Beverage $23,474 1,012 payments
  3. Consulting Fee $15,602 12 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,188 7 payments
  5. Travel and Lodging $7,562 29 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,600 2 payments
  7. Entertainment $581 1 payment
  8. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $19,971 39 payments
  2. Proclaim Family of SCS IPGs $14,637 110 payments
  3. Proclaim DRG IPG $12,931 29 payments
  4. IonicRF Generator $9,090 12 payments
  5. PROCLAIM Neuromodulation $8,697 126 payments
  6. INTELLIS ADAPTIVESTIM $5,437 76 payments
  7. OSTEOCOOL RF ABLATION $3,600 1 payment
  8. Proclaim IPG $3,577 89 payments
  9. Neuromodulation Dspsbls and Accs $2,800 1 payment
  10. SYNCHROMED $2,073 2 payments
  11. Other $20,437 667 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $460 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

6,685

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$261,242

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

65.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,987 $51,643
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,774 $39,399
Xtampza Er Oxycodone Myristate Brand 53 $38,059
Oxycontin Oxycodone Hcl Brand 33 $37,707
Nucynta Tapentadol Hcl Brand 12 $20,299
Buprenorphine Generic 49 $13,463
Fentanyl Generic 92 $10,551
Gabapentin Generic 418 $6,519
Oxycodone Hcl Generic 287 $6,051
Pregabalin Generic 141 $5,863

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$366,475

Of which drugs: $6,095

Medicare patients

653

Average age 71

Services billed

9,906

397 women, 256 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 40%
Diabetes 37%
Ischemic heart disease 32%
Chronic kidney disease 31%
COPD 29%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 375 6,893 $5,026

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
$33 — —
UBRELVY
$8 — —
QULIPTA
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record